These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10585606)

  • 1. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.
    Kuriakose MA; Chen FA; Egilmez NK; Jong YS; Mathiowitz E; DeLacure MD; Hicks WL; Loree TL; Bankert RB
    Head Neck; 2000 Jan; 22(1):57-63. PubMed ID: 10585606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.
    Iwanuma Y; Chen FA; Egilmez NK; Takita H; Bankert RB
    Cancer Res; 1997 Jul; 57(14):2937-42. PubMed ID: 9230205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model.
    Egilmez NK; Jong YS; Hess SD; Jacob JS; Mathiowitz E; Bankert RB
    J Immunother; 2000; 23(2):190-5. PubMed ID: 10746545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
    Hess SD; Egilmez NK; Shiroko J; Bankert RB
    Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model.
    Egilmez NK; Jong YS; Iwanuma Y; Jacob JS; Santos CA; Chen FA; Mathiowitz E; Bankert RB
    Cancer Immunol Immunother; 1998 Mar; 46(1):21-4. PubMed ID: 9520288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.
    Hess SD; Egilmez NK; Bailey N; Anderson TM; Mathiowitz E; Bernstein SH; Bankert RB
    J Immunol; 2003 Jan; 170(1):400-12. PubMed ID: 12496425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
    Sabel MS; Su G; Griffith KA; Chang AE
    Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.
    Li D; Shugert E; Guo M; Bishop JS; O'Malley BW
    Arch Otolaryngol Head Neck Surg; 2001 Nov; 127(11):1319-24. PubMed ID: 11701067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
    Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SCID mouse reaction to human peripheral blood mononuclear leukocyte engraftment. Neutrophil recruitment induced expression of a wide spectrum of murine cytokines and mouse leukopoiesis, including thymic differentiation.
    Santini SM; Rizza P; Logozzi MA; Sestili P; Gherardi G; Lande R; Lapenta C; Belardelli F; Fais S
    Transplantation; 1995 Dec; 60(11):1306-14. PubMed ID: 8525526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model.
    Chen FA; Kuriakose MA; Zhou MX; DeLacure MD; Dunn RL
    Head Neck; 2003 Jul; 25(7):554-60. PubMed ID: 12808659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells.
    Broderick L; Yokota SJ; Reineke J; Mathiowitz E; Stewart CC; Barcos M; Kelleher RJ; Bankert RB
    J Immunol; 2005 Jan; 174(2):898-906. PubMed ID: 15634912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
    Murphy WJ; Conlon KC; Sayers TJ; Wiltrout RH; Back TC; Ortaldo JR; Longo DL
    J Immunol; 1993 Apr; 150(8 Pt 1):3634-42. PubMed ID: 8468492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.
    Simpson-Abelson MR; Sonnenberg GF; Takita H; Yokota SJ; Conway TF; Kelleher RJ; Shultz LD; Barcos M; Bankert RB
    J Immunol; 2008 May; 180(10):7009-18. PubMed ID: 18453623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice.
    Sun R; Zhang J; Zhang C; Zhang J; Liang S; Sun A; Wang J; Tian Z
    Cell Mol Immunol; 2004 Apr; 1(2):129-36. PubMed ID: 16212900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.